Comparison 5. Gluco+IFN versus Control+IFN (Caucasian and Asian trials) at maximal follow‐up.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Loss of HBeAg	13	790	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [1.03, 1.92]
1.1 Caucasian trials	10	575	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.27 [0.90, 1.78]
1.2 Asian trials	3	215	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.42 [1.12, 5.24]
2 HBeAg to anti‐HBe seroconversion	8	554	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.26 [0.87, 1.82]
2.1 Caucasian trials	7	494	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.21 [0.83, 1.76]
2.2 Asian trials	1	60	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.38 [0.55, 20.78]
3 Loss of HBsAg	11	705	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [0.77, 2.59]
3.1 Caucasians	9	566	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.63 [0.86, 3.09]
3.2 Asiatics	2	139	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.35 [0.05, 2.49]
4 Loss of HBV DNA	13	790	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.51 [1.12, 2.05]
4.1 Caucasian trials	10	575	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.35 [0.95, 1.90]
4.2 Asian trials	3	215	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.32 [1.20, 4.48]
5 Normalisation of ALT or AST activities	9	583	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.12 [0.78, 1.62]
5.1 Caucasian trials	8	507	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.99 [0.67, 1.48]
5.2 Asian trials	1	76	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.11 [0.86, 5.18]